- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
SGLT-2 inhibitors better than DPP-4 inhibitors in frail diabetes patients
Australia: Sodium-glucose cotransporter-2 inhibitors may be preferred to dipeptidyl peptidase-4 inhibitors for reducing rates of major adverse cardiovascular events, heart failure hospitalizations, and all-cause mortality in frail people with type 2 diabetes, states an article published in the Frontiers in Pharmacology.
FDA-approved Sodium-glucose cotransporter-2 inhibitors (SGLT-2Is) are prescribed to lower blood sugar in adults with type 2 diabetes. Studies have shown that SGLT2 inhibitors are also beneficial in reducing heart failure (HF) hospitalizations and major adverse cardiovascular events (MACE) in general type 2 diabetes populations. However, those with frailty are typically excluded from the studies despite their high prevalence of diabetes. There is increasing interest in whether treatment benefits and risks in general older populations can be extended to frail people.
Frailty is a medical condition closely related to diabetes and a risk factor for diabetes-related complications. Frail people have over 5-times higher odds of hospitalization and a 35% increased risk of mortality compared to non-frail individuals with diabetes. SGLT-2Is and dipeptidyl peptidase-4 inhibitors may be preferred over sulfonylureas and insulin in people at high risk of hypoglycemia such as those who are frail. It remains unclear whether SGLT-2Is or DPP-4Is have the same benefits and risks in frail people with type 2 diabetes compared to non-frail people with type 2 diabetes.
Wood S, Monash University, Australia and colleagues conducted a study to determine whether SGLT-2Is vs. dipeptidyl peptidase-4 inhibitors (DPP-4Is) are associated with reductions in MACE, HF hospitalizations, and mortality in frail people with type 2 diabetes.
Researchers included 32,043 patients, (aged ≥30 years) with type 2 diabetes discharged from a hospital in the cohort. They received SGLT-2Is or DPP-4Is within 60 days of discharge. Follow-up commenced 60 days after initial discharge, and MACE, HF hospitalization, and mortality were recorded. Analyses were stratified into frailty quartiles according to Hospital Frailty Risk Scores(HFRSs). Cox proportional hazards regression with competing risks and stabilized inverse probability of treatment weights (IPTWs), was used to generate subdistribution hazard ratios (sHRs)
Key findings of the study,
• Overall, SGLT-2I versus DPP-4I recipients had lower rates of MACE (sHR 0.51), HF hospitalization (sHR 0.42), and mortality (HR 0.38).
• People with HFRSs in the fourth quartile who received SGLT-2Is versus DPP-4Is also had reduced rates of MACE (sHR 0.37), HF hospitalization (sHR 0.43), and mortality (HR 0.32).
The authors conclude that study provides preliminary evidence to suggest that SGLT-2Is may be preferred to DPP-4Is in the treatment of frail people living with type 2 diabetes as it showed a reduced rate of MACE, HF hospitalizations, and all-cause mortality. These findings may help the development of updated type 2 diabetes clinical practice guidelines.
Reference:
Wood SJ, Bell JS, Magliano DJ, Shaw JE, Cesari M, Ilomaki J. Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recently Hospitalized. Front Pharmacol. 2022 Jul 12;13:886834. doi: 10.3389/fphar.2022.886834.
BDS
Dr. Hiral patel (BDS) has completed BDS from Gujarat University, Baroda. She has worked in private dental steup for 8years and is currently a consulting general dentist in mumbai. She has recently completed her advanced PG diploma in clinical research and pharmacovigilance. She is passionate about writing and loves to read, analyses and write informative medical content for readers. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751